Press Release

Gensight Biologics announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting

Paris, France, May 30, 2024, 7:30 pm CEST – The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, met.on May 29, 2024, at 9:00 am CEST at the Company's headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.The General Meeting was chaired by Laurence Rodriguez, Chief Executive Officer of the Company.

All resolutions recommended by the Board and submitted to the Combined General Meeting were adopted with the exception of the A and B resolutions which were rejected, in accordance with the recommendations of the Board of Directors. The quorum on first convening amounted to 46.81%.

The results of the vote by resolution are available on the Company's website in the Investors section (www.gensight-biologics.com/investors-media)

Contacts

GenSight Biologics
Chief Financial Officer
Ivan Tortet
itortet@gensight-biologics.com

LifeSci Advisors
Investor relations
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 (0)76 735 01 31

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage, developed for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.